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Abstract
Background: Human renal cell carcinoma (RCC) is very resistant to chemotherapy. ABT-737 is a novel inhibitor of anti-
apoptotic proteins of the Bcl-2 family that has shown promise in various preclinical tumour models.
Results: We here report a strong over-additive pro-apoptotic effect of ABT-737 and etoposide, vinblastine or paclitaxel 
but not 5-fluorouracil in cell lines from human RCC. ABT-737 showed very little activity as a single agent but killed RCC 
cells potently when anti-apoptotic Mcl-1 or, unexpectedly, A1 was targeted by RNAi. This potent augmentation 
required endogenous Noxa protein since RNAi directed against Noxa but not against Bim or Puma reduced apoptosis 
induction by the combination of ABT-737 and etoposide or vinblastine. At the level of mitochondria, etoposide-
treatment had a similar sensitizing activity and allowed for ABT-737-induced release of cytochrome c.
Conclusions: Chemotherapeutic drugs can overcome protection afforded by Mcl-1 and A1 through endogenous 
Noxa protein in RCC cells, and the combination of such drugs with ABT-737 may be a promising strategy in RCC. 
Strikingly, A1 emerged in RCC cell lines as a protein of similar importance as the well-established Mcl-1 in protection 
against apoptosis in these cells.
Background
Renal cell carcinoma is the most common (85%) malig-
nant tumour of the kidney. Although the disease can be
cured by removal of the kidney in cases of localized dis-
ease, about 20% of patients have detectable metastatic
disease at the time of diagnosis, and 20 - 40% of patients
develop metastases following surgery. The 2 year survival
of patients with metastatic disease is under 20% [1,2],
reflecting the poor response of the disseminated tumour
to chemo- or radiotherapy.
This resistance is at least in part the result of a low sen-
sitivity of the tumour cells to apoptosis induction by these
agents. Chemotherapeutic drugs are generally recognized
as inducers of mitochondrial apoptosis, and the efficiency
of this process is a determinant of the drug response [3].
Mitochondrial apoptosis is largely regulated by the Bcl-2
family of proteins [4]. This family contains both pro- and
anti-apoptotic members. Apoptosis is initiated by one or
several proteins from the BH3-only subgroup (eight pro-
teins that are structurally related to each other only in
their short alpha-helical BH3-domain are accepted by the
majority of authors although more have been proposed),
which then activate the effectors Bax/Bak. The anti-
apoptotic proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1)
prevent this activation. Full activation of Bax or Bak
results in the release of cytochrome c from mitochondria,
the cytosolic activation of caspases and apoptosis [3].
How the activation of Bax/Bak by BH3-only proteins
occurs molecularly and which members of the subgroups
interact during apoptosis induction is a matter of dispute
[5-7].
Anti-apoptotic Bcl-2 proteins can bind BH3-only pro-
teins through their BH3-domains although with surpris-
ingly strongly varying affinities [8]. This has engendered
the model that anti-apoptotic proteins normally keep
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Bax/Bak inactive until saturated by BH3-only proteins
(alone or in combination), which will allow auto-activa-
tion of Bax/Bak [6]. Others favour a model where Bax/
Bak have to be activated through BH3-only proteins
although this has proved difficult to show experimentally
[9,10]. It is clear however that some BH3-only proteins
can bind to all anti-apoptotic proteins (such as the BH3-
only proteins Bim and Puma) while for instance Bad can
bind only Bcl-2, Bcl-XL, Bcl-w but not Mcl-1 or A1. The
opposite is the case for the BH3-only protein Noxa,
whose binding appears to be restricted to Mcl-1 and A1
[8]. Extensive experimental evidence shows that the two
anti-apoptotic groups of proteins, Bcl-2, Bcl-XL, Bcl-w on
one hand and Mcl-1 and A1 on the other both have to be
targeted to induce apoptosis [3].
Recently, feasibility of a new approach to apoptosis
induction has been demonstrated in a range of tumour
cells, namely the specific targeting of anti-apoptotic Bcl-2
proteins. One substance, ABT-737 has already been
tested in a number of preclinical models in vitro and in
animals and the orally better bioavailable derivative ABT-
263 is at present in clinical studies [11-13]. ABT-737
binds with high affinity to the BH3-binding cleft in Bcl-2,
Bcl-XL and Bcl-w but not Mcl-1 or A1 [11,14]. A number
of malignancies show response to treatment with ABT-
737 as single agent while more are sensitive to the combi-
nation of ABT-737 with other chemotherapeutic drugs
(for review see [15,16]). The binding pattern of ABT-737
to anti-apoptotic proteins suggested that apoptosis resis-
tance due to high expression of Bcl-2 would be overcome
but the expression of Mcl-1 or A1 would provide protec-
tion. A number of studies have investigated this resis-
tance to ABT-737 and have found consistently that Mcl-1
can indeed confer resistance to ABT-737 while experi-
mental approaches that down-regulate Mcl-1 sensitize
tumour cells to ABT-737 (reviewed in [16]). Since down-
regulation of Mcl-1 has this strong effect, A1 seems to
play no role in resistance to ABT-737 and it has been said
that A1 is not expressed in most tumours although this
may be a problem of sensitivity of A1 protein detection
[14]. However, especially in haematological tumours a
role of A1 has been found [17-19], and over-expression of
A1 in mice has been described to contribute to tumori-
genesis [20].
In RCC cells, easily detectable levels of Bcl-2 are
expressed [21], and some association of high Bcl-2-
expression with a poor prognosis in RCC has been
described [22]. We have found recently that the expres-
sion of the BH3-only protein Bim was reduced in RCC
[23], which may contribute to low drug sensitivity in this
tumour entity. Although the binding capacity of Bim in
terms of anti-apoptotic Bcl-2 proteins is broader than
that of ABT-737, there is the chance that ABT-737 will
nevertheless overcome apoptosis resistance of RCC when
combined with other chemotherapeutic drugs, for
instance by releasing the little Bim there is from its
sequestration to anti-apoptotic Bcl-2 proteins. We there-
fore undertook this study where we tested for augmenta-
tion of ABT-737-killing by drugs in use as
chemotherapeutic agents against RCC.
In cell lines in vitro, ABT-737 sensitized RCC cells
strongly to apoptosis induction by etoposide, paclitaxel
and vinblastine but not 5-fluorouracil (5-FU). In analyz-
ing the contribution of Bcl-2 family proteins we noticed
that endogenous Noxa protein was required for this sen-
sitization, suggesting that neutralization of Mcl-1 or A1
was achieved only through Noxa. Reduction of Mcl-1
expression by RNAi rendered RCC cells sensitive to ABT-
737 in the absence of additional stimuli. More surpris-
ingly, A1-specific RNAi had a similar sensitizing effect on
RCC cells. RCC cells can thus be killed efficiently if the
'Bcl' group of anti-apoptotic proteins (Bcl-2, Bcl-XL, Bcl-
w) are targeted by ABT-737 and the group consisting of
Mcl-1 and A1 by endogenous Noxa protein.
Results
ABT-737 enhances apoptosis induced by vinblastine, 
paclitaxel and etoposide but not 5-FU in RCC lines
We tested four patient-derived clear cell RCC cell lines
for their sensitivity to ABT-737. ABT-737 on its own was
almost completely inactive. As noted previously, little
apoptosis was induced by any of the chemotherapeutic
drugs used. However, there was a strong, more than addi-
tive pro-apoptotic effect of ABT-737 plus three of the
four other drugs tested. This effect was strongest for
etoposide but still substantial for vinblastine and pacli-
taxel (Figure 1; Additional file 1, Figure S1A and B). No
such effect was seen for the combination of 5-FU and
ABT-737 in any of the lines tested, even at later time
points where 5-FU induced considerable apoptosis on its
own (Additional file 1, Figure S1D). No more than addi-
tive induction of apoptosis (as measured by staining for
active caspase-3) or cell death (detected as PI-staining)
was observed for a range of concentrations of 5-FU and
ABT-737 (Figure 1; Additional file 1, Figure S1A, C and
data not shown). Staining for annexin V-binding gave
similar results as staining for active caspase-3 (Additional
file 1, Figure S1B). Cell death induced by combination
treatment was caspase-dependent as it was blocked by
the caspase-inhibitor zVAD-fmk (Additional file 1, Figure
S1A). ABT-737 thus can sensitize RCC cell lines for treat-
ment with vinblastine, paclitaxel or etoposide.
Etoposide sensitizes for ABT-737 at the level of 
mitochondria
ABT-737 acts on Bcl-2-like proteins, which are at least
predominantly localized on mitochondria. It is assumedZall et al. Molecular Cancer 2010, 9:164
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that cytochrome c is released from mitochondria once all
anti-apoptotic Bcl-2 family members have been neutral-
ized [6] or when certain BH3-only proteins are liberated
to activate Bax or Bak [9] (for a recent discussion see
[24]), and treatment of isolated mitochondria or permea-
bilized cells with a peptide encompassing the Bim BH3-
domain can initiate this release [5]. To obtain further evi-
dence of the collaboration of ABT-737 and etoposide, we
exposed permeabilized RCC cells that had been pre-
treated with etoposide to Bim-peptide or ABT-737. As
shown in Figure 2, Bim-peptide but not ABT-737 induced
the release of cytochrome c from untreated cells from the
cell line RCC-26A. This is in accordance with results in
other cellular models and suggests that Bim-peptide was
able to induce cytochrome c-release because it neutral-
ized all Bcl-2-like proteins while ABT-737 spares Mcl-1
and A1 and therefore is inactive on its own; alternatively,
the Bim-peptide may directly activate Bax or Bak. How-
ever, in cells that had been pre-treated with etoposide for
24 h and then permeabilized, ABT-737 was active in
releasing cytochrome c  (Figure 2). This suggests that
etoposide-treatment had the effect of neutralizing Mcl-1
and/or A1, thereby sensitizing mitochondria for ABT-
737. In line with the results obtained with intact cells, 5-
FU failed to sensitize permeabilized cells to ABT-737-
induced cytochrome c-release (Figure 2). The results
therefore suggest that etoposide but not 5-FU can neu-
tralize Mcl-1 and/or A1, leaving mitochondria sensitive
to ABT-737.
Noxa levels during treatment of RCC cells
Although Mcl-1 can also bind Bim and Puma with high
affinity [8], evidence for regulation of Mcl-1 activity
through Noxa has been presented several times [25]. Fur-
ther, etoposide-treatment seemed able to neutralize Mcl-
1 and/or A1 but had only low apoptosis-inducing activity
on its own, suggesting that other Bcl-2 proteins were not
targeted. This indicated a role of Noxa in the treatment of
Figure 1 Potent augmentation of ABT-737-killing by chemotherapeutic drugs.Cells from clear cell RCC lines 21, 30, 26A and Caci-2 were treated 
with 1 μM ABT-737, 100 nM vinblastine, 200 nM paclitaxel, 200 μM etoposide, 1 mM 5-FU or with the combination of ABT-737 plus chemotherapeutic 
drugs. Apoptosis was quantified by staining for activated caspase-3 at 24 h. Values represent the mean/SEM of at least three independent experi-
ments. Note that ABT-737 on its own induced significant apoptosis in the RCC cell line Caci-2. The difference between ABT-737 alone and ABT-737 + 
5-FU was not statistically significant (* P < 0.04, single treatment versus combination treatment).
U
n
t
r
e
a
t
e
d
V
i
n
b
l
a
s
t
i
n
e
P
a
c
l
i
t
a
x
e
l
E
t
o
p
o
s
i
d
e
5
-
F
U
U
n
t
r
e
a
t
e
d
V
i
n
b
l
a
s
t
i
n
e
P
a
c
l
i
t
a
x
e
l
E
t
o
p
o
s
i
d
e
5
-
F
U
U
n
t
r
e
a
t
e
d
V
i
n
b
l
a
s
t
i
n
e
P
a
c
l
i
t
a
x
e
l
E
t
o
p
o
s
i
d
e
5
-
F
U
U
n
t
r
e
a
t
e
d
V
i
n
b
l
a
s
t
i
n
e
P
a
c
l
i
t
a
x
e
l
E
t
o
p
o
s
i
d
e
5
-
F
U
No ABT-737
ABT-737
RCC-21 RCC-30 Caci-2 RCC-26A
A
c
t
i
v
e
 
C
a
s
p
a
s
e
-
3
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
 
(
%
)
0
20
40
60
80
*
*
*
*
*
*
*
*
*
* *
*
100Zall et al. Molecular Cancer 2010, 9:164
http://www.molecular-cancer.com/content/9/1/164
Page 4 of 12
RCC cells with chemotherapeutic agents since Noxa is
the only BH3-only protein whose binding is limited to
Mcl-1 and A1. We therefore assessed Noxa and Mcl-1
levels in RCC cell lines during treatment with these
drugs. As shown in Figure 3, Noxa protein was undetect-
able in two and very lowly expressed in the other two cell
lines used. In all cell lines, etoposide induced Noxa pro-
tein levels most strongly of the drugs tested but only in
one cell line Mcl-1 was lost concomitantly (RCC-26A). In
two cell lines, the other drugs failed to induce detectable
levels of Noxa while in the other two all of them caused
detectable induction. In these two cell lines, there was no
clear difference between the drugs that potently augment
ABT-737-killing (vinblastine, paclitaxel) and 5-FU, which
did not have this effect. Although the results thus suggest
a participation of Noxa, a number of points are not
explained on the basis of these expression levels.
Loss of expression of either Mcl-1 or A1 sensitizes RCC cells 
to apoptosis induced by ABT-737
As discussed above, the results suggested that etoposide
and other drugs were able functionally to eliminate Mcl-1
and/or A1, enabling ABT-737 to induce apoptosis. In a
number of cells it has been demonstrated that it is the
expression of Mcl-1 that determines resistance to ABT-
737 while A1 has been suggested not to be expressed by
most tumours [14]. We decided to knock down Mcl-1
and A1 individually to test for their contributions to resis-
tance to ABT-737. Clear although incomplete reduction
of Mcl-1 protein by transfection with Mcl-1-specific
siRNA was achieved in the three RCC cell lines used as
well as in one cell line engineered stably to express Mcl-1-
specific shRNA (Additional file 1, Figure S2A). Only very
little A1 protein was detectable by Western blotting,
which may be the result of low levels of expression or of
Figure 2 Etoposide sensitizes RCC cells for cytochrome c-release by ABT-737 from mitochondria.(A), (B), RCC-26A cells were cultured in com-
plete medium (untreated) or treated with 200 μM etoposide or 1 mM 5-FU for 24 h. Cells were permeabilized with 200 μg/ml digitonin in the presence 
of solvent (DMSO, control), a peptide encompassing the Bim BH3-domain (100 μM) or ABT-737 (concentrations as shown, 50 μM in A). Reactions were 
separated into supernatants and insoluble pellets and fractions were analyzed by Western blotting for cytochrome c. Membranes were re-probed with 
a Bak-specific antibody as mitochondrial marker. P, pellet fractions, containing cytochrome c retained by mitochondria. S, supernatant fractions, con-
taining released cytochrome c.
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Figure 3 Expression levels of Noxa, Mcl-1, Bim and A1 in RCC lines treated with chemotherapeutic drugs.Cells from RCC cell lines 21, 26A, 30 
and Caci-2 were treated for 24 h with the indicated drugs (100 nM vinblastine, 200 nM paclitaxel, 200 μM etoposide, 1 mM 5-FU). Total cell lysates 
were assayed for Noxa, Mcl-1 and Bim levels by Western blot analysis. Tubulin served as a loading control. The immunoblots shown here are repre-
sentatives of three separate experiments. The mRNA-levels of A1 were measured by quantitative RT-PCR in cells that had been treated for 24 h with 
etoposide or not. The mean values of untreated controls were normalized to 100%. Data are mean/SEM from three separate experiments.
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low sensitivity of the available antibodies, and we failed to
detect A1 protein in two of the RCC cell lines despite
clear mRNA expression (Additional file 1, Figure S2B, C).
However, A1 mRNA was easily detectable, and a good
reduction was achieved by transfection with specific
siRNA (Additional file 1, Figure S2C; in a melanoma cell
line expressing detectable protein levels of A1, siRNA
against A1 gave a good reduction, see Additional file 1,
Figure S2B). Knock-down of Mcl-1-expression strongly
sensitized RCC cells to ABT-737 (Figure 4A), adding RCC
to the list of cell types where the expression levels of Mcl-
1 determine susceptibility to ABT-737-induced apopto-
sis. Importantly, knock-down of A1 had a similar sensitiz-
ing effect (Figure 4B). There was even noticeable cell
death induction by mere knock-down of A1 in the
absence of additional stimuli (Figure 4B). A second
siRNA directed against a separate site in the A1-mRNA
had a similar sensitizing effect in the RCC cell line tested
(RCC-26A, Additional file 1, Figure S3). The RCC-26A
cell line stably carrying an anti-Mcl-1 shRNA construct
was also sensitive to ABT-737 (Figure 4C). Additional
knock-down of A1 by transient transfection with siRNA
caused further sensitization for ABT-737 treatment (Fig-
ure 4D). These data indicate that resistance to ABT-737
in RCC cells is determined not only by Mcl-1 but also by
expression levels of A1, and both proteins may fulfil simi-
lar functions.
Potent augmentation of ABT-737-killing by etoposide or 
vinblastine requires Noxa
Although the data above show an induction of Noxa upon
treatment with chemotherapeutic drugs, Noxa seemed
unable to cause Mcl-1 degradation in most cases, which
could indicate that Noxa was not involved in apoptosis
induced by combination treatments including ABT-737.
Further, the BH3-only proteins Bim and Puma can also
bind Mcl-1 and A1 [8] and might therefore be responsible
for their neutralisation. To identify the BH3-only protein
that causes this effect, we knocked down Bim, Puma and
Noxa individually by transfection with specific siRNA. As
shown in Additional file 1, Figure S4, the expression of
the target proteins was substantially reduced upon trans-
fection with the relevant siRNA (since basal Noxa protein
levels were difficult to detect, Noxa knock-down was here
done in the presence of etoposide, Additional file 1, Fig-
ure S4C). As shown in Figure 5A and 5B, no reduction of
cell death was seen by the knock-down of Bim or Puma
when RCC-26A or RCC-30 cells were treated with the
combination of etoposide and ABT-737. However, Noxa-
specific siRNA significantly reduced cell death induction
by this combination. Noxa- but not Bim- or Puma-spe-
cific siRNA also inhibited cell death induced by the com-
bination of vinblastine and ABT-737 in RCC-26A (Figure
5A) and RCC-30 (Figure 5B; for the comparative expres-
sion of Bcl-2 family proteins in RCC-26A and 30 see
Additional file 1, Figure S4D). These data strongly suggest
that the neutralisation of either Mcl-1 or A1 by Noxa is
the effect through which chemotherapeutic drugs sensi-
tize RCC cells to apoptosis induction by ABT-737.
These results showed the integrity of an axis where
Noxa regulates the activity of Mcl-1 and A1 in RCC. Since
this axis can also be used by proteasome inhibitors, we
tested whether proteasome inhibition could also sensitize
RCC cells to ABT-737-induced apoptosis. As shown in
Additional file 1, Figure S5A, the proteasome inhibitor
MG132 increased the levels of Mcl-1 and Noxa and
blocked the etoposide-induced loss of Mcl-1 in RCC-26A
cells. The loss of Mcl-1 during treatment with etoposide
still occurred in the presence of zVAD-fmk, indicating
that this loss was not due to cell death (Additional file 1,
Figure S5B). MG132 further sensitized the cells for apop-
tosis induction by ABT-737 (Additional file 1, Figure
S5C). Although etoposide induced p53-protein, the
induction of Noxa by etoposide was independent of p53
(Additional file 1, Figure S5D). One possible explanation
for this is that Mcl-1 (and perhaps A1) protein were stabi-
lised but still inhibited by Noxa-binding.
Discussion
The results of this study show that in vitro ABT-737-kill-
ing of RCC-cells is potently augmented by etoposide, vin-
blastine and paclitaxel but is surprisingly not enhanced
by 5-FU. In the active combinations, the contribution of
the 'traditional' chemotherapeutic drugs was the (at least
in part Noxa-dependent) neutralization of Mcl-1 and/or
A1 at mitochondria. Down-regulation of Mcl-1 sensitized
RCC cells to ABT-737 induced apoptosis. Unexpectedly,
siRNA-targeting of A1 had a very similar effect and loss
of both proteins produced an additive result, suggesting
that the total sum of Mcl-1 and A1 expressed in RCC cells
is required to maintain viability in the presence of ABT-
737.
We had previously found that the expression levels of
Bim correlated with RCC-sensitivity to apoptosis, sug-
gesting that the chemotherapeutic drugs used in part
worked by activating Bim [23]. ABT-737 overcame this
requirement as its pro-apoptotic activity was potently
augmented by Mcl-1- or A1-knockdown. This is surpris-
ing as it suggests that Bim (in the absence of ABT-737) is
activated but unable to neutralize Mcl-1, despite the high
affinity of the Bim BH3-domain for Mcl-1 [8]. However,
recent results in melanoma demonstrate the same effect,
namely that the requirement for Bim is overcome by
ABT-737 [26]. At least these relatively low levels of Bim
therefore seem not to be able to antagonize the protec-
tion afforded by Mcl-1.Zall et al. Molecular Cancer 2010, 9:164
http://www.molecular-cancer.com/content/9/1/164
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Although ABT-737 is active as a single agent in some
cases of tumour cells, it much more commonly requires a
combination partner for efficient induction of apoptosis
[27,28]. It is clear that protection through high expression
levels of Bcl-2 is easily overcome by ABT-737 while
expression of Mcl-1 protects cells against ABT-737 [14],
as does  m ouse  A1 [ 20] .  T he  m ai n c on t ribut io n of  a n y
combination partner, such as genotoxic drugs commonly
used in cancer therapy, must therefore be the neutralisa-
tion of Mcl-1 and/or A1. This is clinically relevant: the
Figure 4 Loss of Mcl-1 or A1 sensitizes RCC cells to apoptosis induced by ABT-737.Cells from RCC cell lines 21, 26A and 30 were transfected with 
20 nM of a control siRNA or with siRNA specific for Mcl-1 (A) or A1 (siRNA 441) (B). 48 h later, cells were treated with 5 μM ABT-737 for 24 h and cell 
death was measured by propidium iodide staining. In some samples 100 μM zVAD-fmk was added 1 h prior to treatment with ABT-737. (C), RCC cell 
line 26A stably expressing Luciferase (control) or Mcl-1-specific shRNA were treated with 1 μM and 5 μM ABT-737 for 24 h and cell death was measured 
by propidium iodide staining. (D), Cells from RCC-26A shLuciferase and shMcl-1 were transfected with control siRNA or A1-specific siRNA (siRNA 441). 
24 h post transfection cells were treated with 0.2 μM and 1 μM ABT-737 and stained with propidium iodide 24 h later. Data are mean/SEM of three 
independent experiments (* P < 0.04, control siRNA versus Mcl-1 siRNA and A1 siRNA; shLuciferase versus shMcl-1).
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Figure 5 Noxa but not Bim or Puma is required for full synergism between ABT-737 and etoposide or vinblastine.Cells from the RCC cell line 
26A (A) or 30 (B) were transfected with 20 nM of the indicated siRNAs (Bim, Puma, Noxa or control; in some experiments a second sequence targeting 
Bim and Puma has been included, #2). 48 h later, cells were treated with ABT-737 (1 μM) plus etoposide (200 μM) or vinblastine (100 nM) as indicated. 
Cell death was determined by propidium iodide staining 24 h later. Values are mean/SEM of at least three independent experiments (* P < 0.03; control 
siRNA versus Noxa siRNA).
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results obtained in pre-clinical studies so far make it
likely that the greatest success of ABT-737/ABT-263 will
be in combination with chemotherapeutic drugs such as
the ones in common use. However, the most potent com-
bination partner will not necessarily be the drug that is
most potent on its own but probably the one that most
potently neutralizes Mcl-1 and A1. Why 5-FU was unable
to cooperate with ABT-737 is unclear. 5-FU and vinblas-
t i n e  o r  p a c l i t a x e l  s e e m e d  s i m i l a r  i n  t h e i r  a c t i v i t y  t o
induce Noxa-levels, and it would therefore be expected
that they are similar in terms of sensitizing RCC cells to
ABT-737. It is possible that additional mechanisms exist
that control Mcl-1 and A1-inactivation consecutive to
Noxa-induction but the existence of such mechanisms is
completely speculative. One possibility is that Noxa is
sequestered, perhaps by co-induction of an additional
protein, and cannot actually bind to Mcl-1 or A1. It is fur-
ther possible that 5-FU, while inducing Noxa, also
increases the levels of Mcl-1/A1, perhaps by stabilizing
the protein, which might counteract the pro-apoptotic
effect of Noxa. More detailed studies will be required to
clarify this.
In RCC, etoposide and vinblastine required endoge-
nous Noxa for the potent augmentation of ABT-737-kill-
ing. Noxa was first described as a protein induced by
phorbol-ester treatment [29]. Its function as a pro-apop-
totic protein was first described as a transcriptional target
of p53 [30]. Noxa can also be a transcriptional target of
interferon-signalling and viral infection [31,32]. Noxa is
further induced by treatment with proteasome inhibitors
although this has, in melanoma, been suggested to be an
indirect effect through the activation of c-myc [33]. RCC
cells have usually wt p53 but p53 seems to be non-func-
tional due to a dominant negative inhibitor [34,35].
Etoposide was found to induce p53 although the knock-
down of p53 had very little effect on Noxa-induction in
RCC, consistent with the concept that RCC do not have
functional p53. The c-myc pathway has recently been
suggested to be activated in clear cell RCC although Noxa
was not identified as an up-regulated gene in that study
[36]. How Noxa is activated by the drugs used here is
therefore not clear.
It was surprising to note that Mcl-1 is not necessarily
degraded upon treatment of RCC cell lines with agents
that sensitize for ABT-737; the only situation where we
observed such a decrease was treatment of one of the cell
lines with etoposide. However, even in situations where
Mcl-1 was not degraded Noxa was clearly involved in
sensitization towards ABT-737, as shown by knock-down
experiments. It has been suggested that Mcl-1 has to be
degraded by the proteasome upon Noxa binding in order
to be inactivated, and inhibition of the proteasome pre-
vented the loss of Mcl-1 function [37]. This is an intrigu-
ing observation but molecularly unclear: why does Noxa
when bound to Mcl-1 not suffice to neutralize its func-
tion? Moreover, there are now a number of reports show-
ing that proteasome inhibitors can sensitize tumour cells
to ABT-737, which indicates that they neutralize Mcl-1.
We have found the same sensitization to ABT-737 by
MG132 in our RCC cell lines in this study. Molecular
details are uncertain but it seems clear on the basis of our
results that Mcl-1 does not have to be degraded for the
sensitization of RCC cells to ABT-737. Since targeting of
A1 was also able to sensitize RCC cells, it is a possibility
that the primary function of Noxa in these cases was to
neutralize the function of A1 rather than Mcl-1.
A1 is a less well-investigated member of the established
anti-apoptotic Bcl-2 protein group. A1 may not be
expressed, at least not at high levels in many cells [14,37].
It is also possible that A1 has a very high turnover, as
indeed has been suggested in a previous study. A1 mRNA
was easily detectable in the cell lines we tested although
we were able to detect only an uncertain signal by West-
ern blotting. It is therefore possible that the main regula-
tion of A1 occurs by regulating its stability. In malignant
B cells, A1 has recently been described to play important
roles in regulating cell survival [17,18]. As far as we know,
no such role has been found in solid tumours. Intrigu-
ingly, the knock-down of either Mcl-1 or A1 was suffi-
cient to sensitize RCC cells to ABT-737, suggesting that
both proteins are necessary for survival in the presence of
ABT-737. This is surprising since a distinct molecular
role of Mcl-1 has been suggested, namely the sequestra-
tion of Bak. In that study, Bak was found to be seques-
trated by Mcl-1 and by Bcl-XL while A1 was unable to
f u l f i l  t h i s  f u n c t i o n  [ 3 7 ]  a l t h o u g h  a  m o r e  r e c e n t  s t u d y
found that A1 could interact with and inhibit Bak [19].
Clearly, more work is required to clarify this.
In summary, both anti-apoptotic Bcl-2 proteins Mcl-1
and A1 determine the level of resistance to ABT-737 in
RCC cells, and this layer of protection is disrupted by
etoposide, vinblastine and probably other drugs. To
understand tumour cell apoptosis in more detail and to
devise rational strategies to induce apoptosis therapeuti-
cally, a better understanding of A1 function may be
expected to be helpful.
Methods
Cell lines and materials
Human, patient-derived clear-cell renal cell carcinoma
lines RCC-21, RCC-26A, RCC-30 and Caci-2 were from
the German Cancer Research Centre, Heidelberg, Ger-
many. Cells were maintained in RPMI-1640, supple-
mented with 10% foetal calf serum (FCS), 100 U/ml
penicillin and 0.1 μg/ml streptomycin (PAA, Berlin, Ger-
many) at 5% CO2, 37°C humidified atmosphere. Etopo-
side, paclitaxel, vinblastine and 5-fluoruracil were
obtained from Sigma-Aldrich (Steinheim, Germany).Zall et al. Molecular Cancer 2010, 9:164
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ABT-737 was kindly provided by Dr. Saul Rosenberg and
Dr. Steve Elmore (Abbott Laboratories, Abbott Park, NJ,
USA).
Detection of apoptosis and cell death
Cells from RCC lines were treated with the indicated
drugs, harvested and washed twice in PBS, following
staining with propidium iodide (5 μg/ml) in PBS or
annexin V in binding buffer (10 mM Hepes pH 7.4, 140
mM NaCl and 2.5 mM CaCl2) and analysed within 10
min. by flow cytometry (FACS Calibur, Becton Dickin-
son, Franklin Lakes, NJ, USA). For detection of apoptosis,
cells were fixed in 4% paraformaldehyde in PBS for 10
min. at room temperature and stained with monoclonal
anti-active-caspase-3 antibody (clone C92-605, BD
Pharmingen) in permeabilisation buffer (0.5% BSA and
0.75% saponin (Sigma-Aldrich) in PBS). Cells were
washed in permeabilisation buffer and stained with
FITC-conjugated anti-rabbit IgG secondary antibody
(Dianova, Hamburg, Germany). Flow cytometric analysis
was performed using a FACS Calibur (Becton Dickinson).
In some experiments cells were incubated with 100 μM
zVAD-fmk (Bachem, Heidelberg, Germany) 1 h prior to
cell death induction.
Immunoblotting
Cells were lysed in buffer containing 1% Triton X-100, 50
mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA and
protease inhibitor cocktail (Roche, Mannheim, Ger-
many). Equal amounts of protein extracts were subjected
to SDS-PAGE and transferred to nitrocellulose. Equal
loading was confirmed by detection of tubulin using a
specific antibody (clone DM 18, Sigma). Membranes
were probed with antibodies directed against Bcl-2 (clone
Bcl-2/100, BD Pharmingen), Bcl-XL (polyclonal #2762,
Cell Signaling, Danvers, MA, USA), Mcl-1, cytochrome c
(clone 22 and clone 7H8.2C12, BD Pharmingen,), Noxa
(clone 114C307.1, Alexis, PA, USA,), Bim (polyclonal,
B7929, Sigma), Bax, Bak (polyclonal, NT #06-499 and
polyclonal, NT #06-536, Upstate, Lake Placid, NY, USA),
Bcl-w (clone 31H4, #2724; Cell Signaling), Puma, Bfl-1/
A1 (polyclonal #4976 and polyclonal #4647, Cell Signal-
ing) and p53 (clone 1C12, Cell Signaling). Secondary anti-
bodies were horseradish peroxidase conjugated anti-
mouse IgG or anti-rabbit IgG antibodies (Sigma). Pro-
teins were visualized using an enhanced chemilumines-
cence detection system (GE Healthcare,
Buckinghamshire, UK).
RNAi and quantitative reverse transcriptase PCR
Cells from RCC lines were transfected with 20 nM of
siRNA (depicted is the 19 nt portion in the sense strand
of the targeted mRNA) specific for human Mcl-1 (5'-
GGUUUGGCAUAUCUAAUAA-3'), Bfl-1/A1 (441 5'-
GGAAGAAUUGUAACCAU-3' and 511 5'-CGGAU-
GUGGAUACCUAUAA-3'), Bim (5'-GGAAGAAUU-
GUAACCAUAU-3' and #2 5'-CCACUAUCUCAGU
GCAAUG-30), Puma (5'-CCGAGAUGGAGCCCA-
AUUA-3' and #2 5'-CCUGGAGGGUCCUGUACAA-3'),
Noxa (5'-AGUCGAGUGUGCUACUCAA-3') or p53 (5'-
GUACCACCAUCCACUACAA-3') and a control siRNA
(5'-GCGCAUUCCAGCUUACGUA-3'), containing a
random sequence that does not match a sequence within
the human or murine genome, using Lipofectamine
RNAiMAX reagent according to the manufacturer's
instructions (Invitrogen, Carlsbad, CA, USA). For genera-
tion of RCC cell line 26A stably expressing Mcl-1-specific
shRNA, RNAi sequences targeting Mcl-1 (5'-ACGCG-
GUAAUCGGACUCAA-3') and Luciferase mRNA (5'-
GUGCGCUGCUGGUGCCAAC-3') were cloned in the
GFP-expressing lentiviral vector pLVTHM (Dr. Didier
Trono, Lausanne). Production of lentiviral particles was
done by transfecting 293 FT cells (Invitrogen) together
with packaging vectors pMD2.G and psPAX2 (Dr. Didier
Trono, Lausanne). At 48 h post transfection with siRNA,
cells were assayed for gene knockdown or were used for
further experiments. Total RNA was extracted from RCC
lines after siRNA knockdown using RNeasy mini kit (Qia-
gen, Hilden, Germany) and analysed by quantitative RT-
PCR. RNA (1 μg) was reverse transcribed using Expand
Reverse Transcriptase and poly (dT) oligonucleotide
(Roche) according to the manufacturer's protocol. Quan-
titative PCR was performed using the LightCycler Taq-
Man Master Kit together with the Universal ProbeLibrary
system (Roche). Relative gene expression is expressed as
the ratio of the expression level of the gene of interest to
that of hypoxanthine-phosphoribosyl-transferase
(HPRT) RNA determined in the same sample.
Cytochrome c-release assay
Untreated or treated cells from the RCC-26A line (2 × 105
cells per sample) were harvested and permeabilised in
sample buffer (20 mM HEPES pH 7.2, 100 mM KCl, 5
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 250 mM sucrose
and protease inhibitor cocktail (Roche)), containing 200
μg/ml digitonin (Sigma-Aldrich). Cells were incubated
for 60 min. at 30°C in the presence of BH3-only oligopep-
tide Bim (100 μM) or ABT-737 (1 μM, 5 μM and 50 μM).
Bim-peptide (sequence MRPEIWIAQERRRIGDEFNA)
was synthesized at Biosynthan GmbH (Berlin, Germany).
Cells were then centrifuged for 10 min. at 13000 × g to
separate them into pellet and supernatant fractions. Sam-
ples were adjusted to equivalent volumes with 4× SDS
sample loading buffer and were subjected to immunob-
lotting.Zall et al. Molecular Cancer 2010, 9:164
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c; DMSO: dimethylsulfoxide; EDTA: ethylene diamine tetraacetic acid; EGTA:
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noglobulin G; KCL: potassium chloride; MgCl2: magnesium chloride; Mcl-1:
myeloid cell leukemia sequence 1; NaCl: sodium chloride; Noxa: (Latin for dam-
age) phorbol-12-myristate-13-acetate-induced protein 1; p53: transformation
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